Quality By Design: The Future Of Automated Pharmaceutical Labeling

In Vivo CAR-T And Gene Editing: The Manufacturing Reality Behind The Promise

Advancing Therapeutic Discovery With High-Throughput Electroporation

The Framework For Containment In A Cleanroom

Understanding The Regulatory Landscape For Ophthalmic Drug Products

AI Meets Informed Consent: Opportunity, Risk, and What IRBs Need to See

Design Scalable Downstream Processes With Practical Strategies

How To Activate AI Under GxP, Governance, And Security Constraints

Industry Trends: Connecting Quality, Manufacturing, And Asset Management

Enhancing Gene Editing Outcomes And Safety for Clinical Translation With Next Generation Vectors

Comprehensive Bioprocess Control: Substrate, Metabolite And Product Analysis

A Novel Cell Selective Lentiviral Platform For CAR-T Engineering

Maximizing Performance And Quality In Fed-Batch And Perfusion-Based IgG Productions Customer Interview

How MacroGenics Increased mAb Titers By Up To 80% In Scale-Up

Boost CHO Cell Protein Production By Up To 146% With Efficient-Pro™ Feed Solutions

Driven By Performance: Empowering Biotech Innovation From Lab To Life

Defined Media, Defined Results: Scaling E. coli From Bench To Fermenter

DynaDrive S.U.B. Video Series

Digital Design Meets Proven Performance: The Future Of Single-Use Assemblies

DynaDrive Single-Use Bioreactors Drilled-Hole Sparge Technology

DynaDrive Single-Use Bioreactors - One Reactor, Many Volumes

Scale With Confidence From Bench To Commercial Production

Why Is The Bioreactor Square? The Geometry Behind Exceptional Mixing

Aegis Film For DynaDrive Single-Use Bioreactors

Applying AI And Rapid Prototyping To Media And Process Development

Five Reasons To Choose Single-Use Bioreactors

Go Beyond Custom Media Screening And Prototyping

Take The Lead With The Gibco CHOvantage™ GS Cell Line Development Kit

From Lab To Commercialization: Simplifying Bioprocess Scale-Up

High Efficiency Cell Engineering From Concept To Clinic

Audience Q&A | Inside The Most Promising Non-Viral Approaches To Genetic Engineering

Elucidating The Role Of IL-18 In NSCLC Integrated Analysis

Validation Of An LCMS Hybrid Assay With EVOSEP Cleanup

Base Editing's Advantages When Combined With Non-Viral Delivery Methods

Electroporation As A Method For Genetic Modification

How To Best Optimize mRNA Production Workflows

Ori Spotlight: Building Early-Phase CGT Infrastructure For Translational Success

Using ddPCR Technology To Characterize The Poly(A) Tail Content

Can Kinetics Provide Detailed Information About Binding Interactions?

An All-In-One Solution For Residual DNA Quantitation

NK Cells' Role In Non-Viral Approaches To Genetic Engineering

The Future of In Vivo Gene Editing and Clinical Translation with Precision Biosciences' Cassie Gorsuch, Ph.D.

Redefining CAR-T Timing and Patient Access with Allogene Therapeutics' Dr. Zachary Roberts

Building Integrated cGMP Systems for Autologous Cell Therapies with MassGen's Tatyana Matveeva, Ph.D.

Rewriting Disease Biology Through LSD1 Inhibition with Oryzon's Carlos Buesa, Ph.D.

Advancing Early Detection in Rare Cancers with Catriona Jamieson, M.D., Ph.D.

Regulatory Flexibility in CGT: Key Shifts and Implications with Monika Swietlicka

Scaling CRISPR For Rare Disease With Aurora Therapeutics' Dr. Edward Kaye

Simplifying Friction in Cell Therapy Clinical Trials with Dr. Panteli Theocharous

Inside a Breakthrough HER2 Immunotherapy for PMO with OS Therapies' Paul Romness

Building Safer CRISPR Medicines for CVD with Scribe Therapeutics' Benjamin Oakes

Advancing Off-The-Shelf CRISPR CAR-T Therapies Into The Community Setting With Caribou Biosciences' Rachel Haurwitz

The Editors' Roundtable: A 2025 Retrospective of the Life Sciences Industry

High Efficiency Cell Engineering From Concept To Clinic

Thermo Fisher Scientific Customer Experience Center Overview

The Impact Of Cell Therapy Manufacturing On Patient Access And Experience

Addressing Rapid Biomanufacturing Capacity Needs

How MacroGenics Increased mAb Titers By Up To 80% In Scale-Up

Bridging The Gap Between Lab Development And GMP Manufacturing

Sampling In The PBS Mini

Cell Culture Media Manufacturing, Grand Island, NY

HyPerforma DS 300 Single-Use Mixer Overview

Freezing Studies For Single-Use Solutions: Controlled-Rate (Part 1)

Single-Use Centrifuge Cinematic

Building Strong Data Foundations And Smart Logistics For Scalable CGT Development

Regulatory And Biosafety Testing Expertise

A Concept-To-Commercial Gene Therapy CDMO

The Power Of Partnerships And The Rise Of iPSC

Early-Phase Whole-Body PK

What Is Causing Limited Bioavailability

Biopharma Resilience: Bionova Scientific Talks Capacity, Speed, And Agility

Closing Ancillary Processes: The New Bottleneck In Cell and Gene Therapy

Selecting The Right CMO For Your Gene Therapy

Bridging The Gap Between Lab Development And GMP Manufacturing

Robust And Consistent Frozen Storage And Shipment

Supporting The Global Biopharma Industry With Single-Use Capacity Expansion

Supply Chain And Operational Challenges Facing mRNA

A Dedicated Team To Safely Store Your Cell And Virus Banks

Inventory Management, Staff Training, And Timeline Optimization

Risk Mitigation Strategies

Regulatory Considerations For An Optimized Cold Chain

Breaking Down Shipping

Microcarrier Separation Systems

Balancing Innovation With Manufacturability When GMP-Grade Is Unavailable

Storing Your Banks With Ease And Confidence

Enhancing Particle Recovery And Infectivity In Viral Vector Purification

Smart Manufacturing Decisions For Scalable Gene Therapy Success

From Bench To Bioproduction: Scalable MSC Expansion

Cell Handling Across Cell Types

High-Precision Fluid Management For Cell-Based Applications

Enhancing CGT Analytics And Quality Control With Digital PCR

Non-Viral Delivery Of Complex Cargos For Large-Scale CAR-T Manufacturing

Quantifying Potency In Cell & Gene Therapy

Integrated Reagent Solutions For CAR-T/NK Development And Manufacturing

How Raw Materials, Media Composition, and Process Decisions Shape Therapy Development

Entegris Cell & Gene Tech Expo April 2026: Cell Therapy

Fostering Closed-System Innovation For Flexibility And Scalability

Distributed Manufacturing for CGT: Rent, Lease, or Buy in an Era of Overcapacity?

Materials Matter: Ensuring Quality Of CGT Materials

Building Smarter Cell Therapies With AI And Synthetic Biology

2026 Regulatory Roadmap

Driving Efficiency, Reducing Costs In Multi-Modal CGT Manufacturing

Viability On The Line: Defining Minimum Quality For CGT Raw Materials

Designing Early Manufacturing For Long-Term Success In CGT

Building The Future Of Cancer Immunotherapy Through Allogeneic NK Cell Innovation

Redefining CGT With Exosomes And EVs

Advancing Gene Delivery: LNPs, Adenovirus, Lentivirus, And More

Unlocking The Potential Of iPSC Therapies In Regenerative Medicine

Emerging Manufacturing Technologies For Cell Therapies

Optimizing Storage Solutions For Allogeneic iPSCs

2025 CGT Regulatory Outlook

Unlocking The Full Potential Of AAV-Mediated Gene Delivery

Inside The Most Promising Non-Viral Approaches For Genetic Engineering

From Bottleneck To Breakthrough: Reimagining The mRNA Therapeutics Supply Chain

Modernizing CAR-T Manufacturing: Is Point Of Care The Future?

Top Strategies To Reduce Off-Target Effects For Safer Genome Editing

Inside Next-Gen Platforms For Cell Therapy Manufacturing

Unlocking The Future Of Allogeneic Cell Therapy For Oncology

Stem-Cell Derived Therapies: From Source To Site

How To Reduce Batch-to-Batch Variation In Cell Therapy Manufacturing

2024 Regulatory Outlook With FDA's Drs. Peter Marks And Nicole Verdun

Considerations For Investing In Your Gene Therapy's Automation Framework

mRNA For Cancer Immunotherapy: 2024 Outlook

Are We There Yet? Roadmap(s) To Higher Quality AAV

Optimizing Your Cold Chain For Cell Therapies

Stability To Scalability: The Future Of Viral Vector Therapies

Regulating The CGT Workflow To Improve Patient Safety

Driving Down COGS: Automation's Role In Cell Therapy Manufacturing

Major Trends In Next-Gen RNA Engineering

Building An In-House Cell & Gene Manufacturing Facility: Best Practices & Lessons Learned

Scaling Cell Therapies Part 2: Establishing Comparability In Manufacturing

Tackling Cell And Gene Therapies' Top 3 Regulatory Impediments

Evaluating Translational Research Tools For CGTs

Scaling Cell Therapies: Auto vs. Allo

Advancements In Targeted mRNA Delivery

Win The CGT Talent Fight: How To Find And Retain Experts

Kite Pharma's Ultimate Supply Chain Test - A Q&A With Their 4-Exec Panel On Overcoming The Pandemic's Disruption

The Therapeutic Potential Of Exosomes

The Future of CRISPR-Engineered Stem Cell Therapies

How The FDA's 2024 Draft Guidances Will Influence CGT Regulation In 2025

CMC Comparability: Transitioning to Commercial Manufacturing with Dr. Nicole Verdun

Navigating Global Regulations, Equity Challenges, And The Future Of Patient Access

What's New for 2024: Dr. Nicole Verdun Offers a Look Inside The Office Of Therapeutic Products

CGT's Main Opportunities To Meet Regulatory Requirements

Prioritizing Quality, Fit, And Supplier Reliability In CGT Materials

How The FDA Strengthens Industry Collaboration

Lower Variability For Viral Titer Determination

Regulatory And Biosafety Testing Expertise

A CDMO Perspective: Bioprocess Automation And Data Management

Race To The Regulatory Finish Line: Dr. Nicole Verdun Talks Efficiencies In Platform Technologies

Strategies To Reduce Regulatory Risks In Gene Therapy

Executive Roundtable: Cell Therapy Predictions For 2025 And Beyond

Challenge #3: Lack Of Animal Models

Making USP Guidance Actionable For CGT Materials

Inside The Phased, Risk-Based Approach For CGT Materials

How The New Administration Could Shape FDA Oversight, Compliance, And Guidance In 2025

Other CGT Regulatory Challenges

mRNA For Cancer Immunotherapy 2024 Outlook | Audience Q&A

Focal Points for 2024: Dr. Verdun and Dr. Marks Talk Regulatory Challenges for Cell-Based Therapies

Challenge #1: The Changing Regulatory Landscape

Simplifying Bioprocess Data Collection

Tackling Cell And Gene Therapies' Top 3 Regulatory Impediments: Audience Q&A

Regulatory Challenges And Future Outlook For iPSC Therapies

Master The 2-Point Calibration Process To Maintain Data Integrity

How Past Gene Therapy Approvals Are Shaping the Future with Dr. Peter Marks

2025 CGT Regulatory Outlook | Audience Q&A

Challenge #2: Rare Or Ultra-Rare Study Design Considerations And Use Of Existing Data

A Straightforward Path Toward Regulatory Compliance & Data Integrity With Your Microbial Testing Systems

Mitigate Clinical Risk In Cell Therapy Development With A GMP Compliant Process

Assessing Residuals In Processing And Fill/Finish For iPSCs

Cell And Gene Therapy Innovations

Future Proof Process Design Through Risk-Focused Decisions, Automation Readiness, And Regulatory Pragmatism

MilliporeSigma Bio-Expo Live February 2025: Upstream Bioprocessing

Patient Data's Impact On CMC Robustness

Bridging Analytical Gaps To Ensure CGT Material Quality

Key Regulatory Challenges, Innovations, And Opportunities For CGT In 2025

Ensuring Consistent Removal Of Residual Impurities

Dr. Peter Marks Talks a Standardized Playbook for Gene Therapy Manufacturing

Why Clinical Requirements Change: Dr. Peter Marks on Pre-IND Meeting Pathways

Congruence And Divergence In Global Regulatory Approvals

Rare Disease Drug Commercialization With Zevra Therapeutics' Neil McFarlane

Scaling Manufacturing For Personalized Cell Therapies With Cellino's Marinna Madrid, Ph.D.

Building A New Antibody Discovery Platform With Infinimmune's Wyatt McDonnell, Ph.D.

From Partnered ASO Therapies To A Wholly-Owned Pipeline With Ionis's Brett Monia, Ph.D.

Implementing A New CEO Strategy With NervGen's Adam Rogers, M.D. And Rich Macary

The Impact Of FDA Risk On Biotech Rewards With CFO And Board Director Allan Shaw

Biosimilars And Complex Medicines For All With RNA Therapeutics' Sarfaraz Niazi, Ph.D.

Radiotherapeutics For Neuroendocrine Tumors With Perspective Therapeutics' Thijs Spoor

Investing In Early-Stage Oncology With Yosemite's Dan McHugh

Commercializing CAR T Cell Therapy With Legend Biotech's Alan Bash

Radiotherapeutics For CNS Cancers With Plus Therapeutics' Marc Hedrick, M.D.

Developing Novel Cancer Drugs On A Budget With Iterion Therapeutics' Rahul Aras, Ph.D.

Validation Challenges Facing Advanced Single-Use Technologies

Aligning Upstream And Downstream Development (Part 2)

Aligning Upstream And Downstream Development (Part 1)

Reprogramming T Cells And Reducing Manufacturing Costs With RegCell's Michael McCullar, Ph.D.

Scaling Regenerative Medicine Production With PolarityBio's Nikolai Sopko, MD, Ph.D.

Pursuing Quality While Maintaining Process Control With Richard Moroney, Ph.D.

Unlocking The Therapeutic Power Of Fibroblasts With Pete O'Heeron And Hamid Khoja, Ph.D.

Supporting The Bioprocessing Workforce In The AI Era With Sanofi's Eric Doerr

Putting Pressure On CDMOs With Herman Bozenhardt

Data Governance And Regulations For AI Use In GMP With Peter Baker

The Editors' Roundtable: A 2025 Retrospective Of The Life Science Industry

Combining AI With Operations Research To Advance Biomanufacturing With Tinglong Dai, Ph.D., and Tugce Martagan, Ph.D.